CytoDyn announces positive results from completed pivotal PRO 140 HIV combination trial
CytoDyn announces that approximately 81% of patients who completed the 25-week CD02 pivotal trial with PRO 140 in combination with existing highly active antiretroviral therapy showed viral load suppression with plasma HIV-1 RNA viral load of less than 50 copies/mL. July 16, 2018